35880-86-5

Upstream product

• 777-37-7 4-chloro-3-(trifluoromethyl)nitrobenzene 
• 15898-43-8 sodium 4-acetamidobenzenesulfinate 
• 1126-81-4 4-acetamidothiophenol 
• 60516-07-6 N-[4-(4-Nitro-2-trifluoromethyl-phenylsulfanyl)-phenyl]-acetamide 

Downstream Products

• 35880-87-6 4'-acetamino-4-amino-2-trifluoromethyl-diphenylsulfone 

Relevant academic research and scientific papers

Anti-bacterial compositions comprising a substituted bis-(4-aminophenyl)-sulfone and a dihydro-folic acid reductase

Disclosed are substituted bis(4-aminophenyl-sulfonees of general formula STR1 wherein R1 is hydrogen, alkyl or cycloalkyl; group, R2 is hydrogen or C1 -C3 alkyl, R3 is nitrile, C1 -C3 alkylaminocarbonyl, di C1 -C3 alkylaminocarbonyl, C3 -C7 N-cycloalkyl-C1 -C3 alkylaminocarbonyl C1 -C3 alkylamino, C1 -C3, di alkylaminocarbonyl alkoxy, alkylaminosulfonyl, di C1 -C3 alkylaminono, diC1 -C3 alkylaminosulfonyl, hydroxy C1 -C3 alkyl, C1 -C3 alkylcarbonyl, amino C1 -C3 alkyl or C1 -C3 alkoxy C1 -C3 alkyl group or, when R1 and R2 are each hydrogen, R3 can be hydroxy, hydroxycarbonyl C1 -C3 alkoxy or di C1 -C3 aminocarbonylalkoxy; or, when R1 is C1 -C3 alkyl or C1 -C3 cycloalkyl and R2 is hydrogen or C1 -C3 alkyl, R3 can also be halogen, trifluoromethyl, nitro, amino, aminosulfonyl, aminocarbonyl, C1 -C3 alkylo, carboxy or C1 -C3 akoxycarbonyl; and R4 is hydrogen or, when R1 and R2 are each hydrogen and R3 is halogen or hydroxy, R4 can also be halogen, hydroxy or C1 -C3 alkoxy; or a nontoxic, pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising such compounds alone and in combination with dihydrofolic acid-reductage inhibitors. The compounds and compositions are useful for their inhibiting effect on bacteria, mycobacteria and plasmodia.

Substituted bis-(4-aminophenyl)-sulfones

Disclosed are substituted bis(4-aminophenyl)-sulfones of general formula STR1 wherein R1 is hydrogen, alkyl or cycloalkyl; group, R2 is hydrogen or C1 -C3 alkyl, R3 is nitrile, C1 -C3 alkylaminocarbonyl, di C1 -C3 alkylaminocarbonyl, C3 -C7 N-cycloalkyl-C1 -C3 alkylaminocarbonyl C1 -C3 alkylamino, C1 -C3, di alkylaminocarbonyl alkoxy, alkylaminosulfonyl, di C1 -C3 alkylaminono, diC1 -C3 alkylaminosulfonyl, hydroxy C1 -C3 alkyl, C1 -C3 alkylcarbonyl, amino C1 -C3 alkyl or C1 -C3 alkoxy C1 -C3 alkyl group or, when R1 and R2 are each hydrogen, R3 can be hydroxy, hydroxycarbonyl C1 -C3 alkoxy or di C1 -C3 aminocarbonylalkoxy; or, when R1 is C1 -C3 alkyl or C1 -C3 cycloalkyl and R2 is hydrogen or C1 -C3 alkyl, R3 can also be halogen, trifluoromethyl, nitro, amino, aminosulfonyl, aminocarbonyl, C1 -C3 alkyl, carboxy or C1 -C3 alkoxycarbonyl; and R4 is hydrogen or, when R1 and R2 are each hydrogen and R3 is halogen or hydroxy, R4 can also be halogen, hydroxy or C1 -C3 alkoxy; or a nontoxic, pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising such compounds alone and in combination with dihydrofolic acid-reductase inhibitors. The compounds and compositions are useful for their inhibiting effect on bacteria, mycobacteria and plasmodia.